8-K/AAcquisitions & DispositionsExhibits & Filings

ABBOTT LABORATORIES 8-K/A Report, Acquisition Completed (Mar 5, 2015)

Filed March 5, 2015For Securities:ABT

Summary

This Form 8-K/A filing from Abbott Laboratories (ABT) on March 5, 2015, serves as an amendment to a previous report filed on February 27, 2015. The primary purpose of this amendment is to provide required financial information related to the completion of the sale of Abbott's developed markets branded generics pharmaceuticals business to Mylan. The transaction involved Abbott receiving 110 million ordinary shares of Mylan N.V. in exchange for this business segment. Investors should note that this filing primarily contains supplementary financial disclosures related to the completed divestiture. While it confirms the asset disposition, the core operational and financial impact of the sale will be detailed in the attached unaudited pro forma consolidated financial information. This information is crucial for understanding Abbott's financial position and strategic focus post-transaction.

Key Highlights

  • 1Abbott Laboratories completed the sale of its developed markets branded generics pharmaceuticals business to Mylan.
  • 2The transaction consideration received by Abbott was 110 million ordinary shares of Mylan N.V.
  • 3This 8-K/A filing amends a previous report to include necessary financial statements and exhibits.
  • 4The filing includes unaudited pro forma consolidated financial information giving effect to the disposition.
  • 5The disposition of assets was the primary event reported, with detailed financial information now being provided.
  • 6Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.

Frequently Asked Questions

The main purpose of this amended 8-K filing was to provide the required financial statements and exhibits, specifically unaudited pro forma consolidated financial information, related to the previously reported sale of Abbott's developed markets branded generics pharmaceuticals business to Mylan.

Abbott Laboratories received 110 million ordinary shares of Mylan N.V. in exchange for the sale of its developed markets branded generics pharmaceuticals business.

The financial impact of the transaction, specifically unaudited pro forma consolidated financial information, is included as Exhibit 99.1 in this filing. Investors should review this exhibit for details on how the disposition affects Abbott's consolidated financial statements.

Yes, the filing confirms that Abbott Laboratories completed the sale of its developed markets branded generics pharmaceuticals business to Mylan. This 8-K/A filing is an amendment to provide the necessary financial disclosures following the completion of that transaction.